2022 Annual Shareholders’ Meeting Results

Fisher & Paykel Healthcare Corporation Limited advises that all resolutions put to the company’s annual shareholders’ meeting held today were passed. The 11 resolutions were:

Resolution 1: To re-elect Lewis Gradon as a director.
Resolution 2: To re-elect Neville Mitchell as a director.
Resolution 3: To re-elect Donal O’Dwyer as a director.
Resolution 4: To elect Lisa McIntyre as a director.
Resolution 5: To elect Cather Simpson as a director.
Resolution 6: To authorise the Directors to fix the fees and expenses of the auditor.
Resolution 7: To approve the issue of performance share rights to Lewis Gradon.
Resolution 8: To approve the issue of options to Lewis Gradon.
Resolution 9: To approve the North America 2022 Employee Stock Purchase Plan.
Resolution 10: To approve the 2022 Performance Share Rights Plan – North America.
Resolution 11: To approve the 2022 Performance Share Option Plan – North America.

All resolutions were decided by poll. The details of the total number of votes cast online, via phone or by proxy on the polls were as follows:
 
Resolution Votes
For		 % Votes Against Abstain Total Votes Cast
Resolution 1: To re-elect Lewis Gradon as a director 417,970,319 99.99% 30,222 83,434 418,083,975
Resolution 2: To re-elect Neville Mitchell as a director 411,128,146 98.36% 6,860,053 95,776 418,083,975
Resolution 3: To re-elect Donal O’Dwyer as a director 410,700,203 98.28% 7,177,829 205,943 418,083,975
Resolution 4: To elect Lisa McIntyre as a director 417,824,318 99.99% 56,047 203,610 418,083,975
Resolution 5: To elect Cather Simpson as a director 417,779,788 99.97% 105,828 198,359 418,083,975
Resolution 6: To authorise the Directors to fix the fees and expenses of the auditor 412,820,609 99.30% 2,902,593 2,360,773 418,083,975
Resolution 7: To approve the issue of performance share rights to Lewis Gradon 406,452,228 97.42% 10,773,351 294,521 417,520,100
Resolution 8: To approve the issue of options to Lewis Gradon 406,325,338 97.39% 10,895,306 299,376 417,520,020
Resolution 9: To approve the 2022 Employee Stock Purchase Plan 416,172,287 99.59% 1,715,840 195,848 418,083,975
Resolution 10: To approve the 2022 Performance Share Rights Plan – North America 415,456,483 99.44% 2,358,647 267,250 418,082,380
Resolution 11: To approve the 2022 Performance Share Option Plan – North America 416,914,483 99.81% 813,161 354,656 418,082,300

Authorised by Raelene Leonard, General Counsel & Company Secretary.

 

About Fisher & Paykel Healthcare

Fisher & Paykel Fisher Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in more than 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.

 

 

Contact

Media:

Karen Knott
GM Corporate Communications
karen.knott@fphcare.co.nz
+64 (0) 21 713 911
 

Investors:

Hayden Brown
Investor Relations Manager
hayden.brown@fphcare.co.nz
+64 (0) 27 807 8073

We value your privacy. Our websites and applications use cookies to function properly and securely.

De-identified Information, as described in our Global Privacy Statement, may be collected and used to support the performance of these sites, and to provide you with a better user experience. Cookie information is not used to promote personalised content on our websites. To learn more about how we use cookies, including examples, go to our Global Privacy Statement.